LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
United StatesFull profile →
Oral cyclic peptides · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
79 matching companiesShowing 1–24 / 79
FDA approved ICOTYDE for plaque psoriasis on 2026-03-17. Its prescribing information reports human exposure and food effects.
United StatesFull profile →
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
Mainland ChinaFull profile →
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
Mainland China / United StatesFull profile →
T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
Mainland ChinaFull profile →
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
Mainland ChinaFull profile →
A U.S. commercial benchmark for oral octreotide, with label evidence for enteric capsule composition and a substantial food effect. Its EU authorization has been withdrawn.
Italy / United StatesFull profile →
AUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
JapanFull profile →
LUPKYNIS is a U.S.-approved oral treatment for lupus nephritis. Its capsule label discloses lipid and surfactant ingredients.
Canada / United StatesFull profile →
The discovery and collaboration partner for ICOTYDE. Its website also lists PN-881 (oral IL-17A/F) and other early oral programs; the company is recorded separately from J&J.
United StatesFull profile →
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
United StatesFull profile →
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
United StatesFull profile →
The website explicitly focuses on cell-permeable, orally available cyclic peptides using machine learning, automated design, synthesis, and testing. No named clinical candidates were disclosed.
United States / AustraliaFull profile →
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
United StatesFull profile →
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
Denmark / SwitzerlandFull profile →
The PDPS-derived oral peptide pipeline includes a myostatin program listed as IND-enabling, plus other oral candidates; it is recorded separately from the radiopharmaceutical peptide pipeline.
JapanFull profile →
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
Mainland ChinaFull profile →
AVR-001 is Hansoh's HS-20118, with an exclusive license outside Greater China. A 2026 announcement proposed a merger with NextCure; the transaction is not recorded as closed.
United StatesFull profile →
HSK47388 is an oral IL-23 inhibitory peptide in Phase 2 for psoriasis. Relative exposure data support its enhancer formulation, while cyclization and absolute oral bioavailability remain unconfirmed.
Mainland ChinaFull profile →
SAL0167 is an internally developed cyclic peptide program for hyperlipidemia that received NMPA clinical trial authorization in 2026. Authorization is not treated as evidence of actual dosing.
Mainland ChinaFull profile →
The website lists oral cyclic peptides NGA-101 (IL-4Rα), NGA-102 (TL1A), and NGA-103 (TSLP). Pipeline stage graphics cannot be verified through text extraction alone.
Mainland ChinaFull profile →
The MO-PION oral macromolecule platform website explicitly lists semaglutide, heparin, and micafungin applications. Micafungin provides a lead for cyclic peptide applications.
Mainland ChinaFull profile →
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
South KoreaFull profile →
ORALINK combines ligand conjugation, lipidation, and excipient strategies. The α4β7 cyclic peptide program with QIC is in lead optimization; its GLP-1 human evidence does not transfer to cyclic peptides.
South KoreaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.